{
  "trial_id": "NCT02371681",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age 18 to 65 years with body weight from 30 kg to 90 kg",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Sputum acid-fast bacilli (AFB) smear positive (at least 1+ on the WHO International Union Against Tuberculosis and Lung Disease scale)",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Likely able to produce approximately 10 mL of sputum per day",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Xpert MTB/RIF-confirmed M.tb",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Rifampin-sensitive pulmonary tuberculosis as indicated by Xpert MTB/RIF",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "ALT <3X upper limit of normal, creatinine <2X upper limit of normal",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Willingness to have samples stored",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Clinically suspected disseminated TB or acuity of illness too much as deemed by clinicians",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Has been treated for tuberculosis within the past 3 years",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Treatment with agents known to have anti-tuberculosis activity (e.g., fluoroquinolones, linezolid) for any indications during the current episode of clinical illness or within 2 months prior to screening, whichever is longer",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Cirrhosis or chronic kidney disease",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Disease complications or concomitant illness that might compromise safety or the interpretation of trial endpoints, such as known diagnosis of chronic inflammatory condition (e.g., sarcoidosis, rheumatoid arthritis, and connective tissue disorder)",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or inhaled corticosteroids, within 2 weeks prior to screening",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Subjects with diabetes, point of care HbA1c above 6.5, or random glucose over 200 mg/dL",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Conditions which compromise the subject s ability to take or absorb oral drugs",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "Patient A is a 30-year-old male with symptoms of cough, profuse nocturnal sweating and loss of appetite. He has a positive sputum culture for Mycobacterium tuberculosis which are sensitive to first-line TB drugs.",
  "_meta": {
    "topic_id": "46",
    "trial_id": "NCT02371681",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}